Wedge Capital Management L L P NC Has $4.51 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Wedge Capital Management L L P NC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,102 shares of the medical equipment provider’s stock after selling 13,812 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Zimmer Biomet were worth $4,505,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Dakota Wealth Management boosted its stake in Zimmer Biomet by 12.8% during the fourth quarter. Dakota Wealth Management now owns 11,831 shares of the medical equipment provider’s stock worth $1,064,000 after buying an additional 1,342 shares in the last quarter. Corbyn Investment Management Inc. MD raised its position in Zimmer Biomet by 4.5% in the fourth quarter. Corbyn Investment Management Inc. MD now owns 33,867 shares of the medical equipment provider’s stock worth $3,045,000 after purchasing an additional 1,447 shares in the last quarter. Czech National Bank raised its holdings in shares of Zimmer Biomet by 3.9% in the 4th quarter. Czech National Bank now owns 52,257 shares of the medical equipment provider’s stock worth $4,699,000 after buying an additional 1,944 shares in the last quarter. Gilman Hill Asset Management LLC grew its position in Zimmer Biomet by 6.7% in the fourth quarter. Gilman Hill Asset Management LLC now owns 33,585 shares of the medical equipment provider’s stock valued at $3,020,000 after acquiring an additional 2,097 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Zimmer Biomet by 69.3% in the 4th quarter. SG Americas Securities LLC now owns 103,462 shares of the medical equipment provider’s stock worth $9,303,000 after acquiring an additional 42,352 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent analyst reports. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Weiss Ratings cut Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 23rd. Finally, Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Trading Down 0.2%

Shares of NYSE ZBH opened at $88.41 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The firm has a 50-day moving average of $92.00 and a 200 day moving average of $94.01. The stock has a market cap of $17.30 billion, a P/E ratio of 24.98, a price-to-earnings-growth ratio of 1.81 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Insider Activity

In other news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.70% of the stock is owned by company insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.